Weight-loss drugs like Ozempic, Wegovy, and Mounjaro are all the rage, and investors are noticing.
Since launching in November, the Tema Obesity and Cardiometabolic ETF (HRTS) is up 24%, crushing the S&P 500's 14.8% returns over the same period.
Pot and his colleagues at Tema are bullish on the weight-loss drug stocks due to the wave of demand they see coming.
Novo Nordisk estimates that only 2% of obesity cases are being treated by weight-loss drugs, Pot said.
4 weight-loss drug stocks to watchPot listed two larger stocks and two smaller ones in the space.
Persons:
Maurits Pot, Janus Henderson, Pot, Goldman Sachs, Geoff Meacham, Charles Barkley, Elon Musk, Whoopi Goldberg, Eli Lilly, Lilly
Organizations:
VanEck Pharmaceutical, Business, World Health Organization, Novo Nordisk, Bank of America, Bank, Nordisk, FDA, Amazon, Therapeutics, Zealand Pharma
Locations:
Tema, GLP, Danish, it's